PubMed Health⌕ Search

Biomedical subjects

S J Rani

Publications and source records attributed to S J Rani.

7 recordsLinked to original sources

The antidepressant efficacy of zimelidine and maprotiline.

In a double-blind group comparison study of 39 patients with primary depressive illness zimelidine in a dose of 200 mg at night demonstrated the same order of antidepressant efficacy as maprotiline in a dose of 150 mg at night after either two or four weeks treatment measured by the amelioration or final score on the Hamilton Rating Scale (HRS) and on the Montgomery & Asberg Depression Rating Scale (MADRS). Both zimelidine and maprotiline demonstrated significant antidepressant activity at 2 weeks compared with 2 weeks prior treatment with placebo measured by amelioration on HRS (paired t 4.1 P less than 0.001, t 2.7 P less than 0.02) or MADRS (paired t 3.5 P less than 0.005, t 5.1 P less than 0.001). An item analysis of the MADRS showed significantly better sleep and appetite in the maprotiline-treated group compared with the zimelidine-treated group which is in accord with the pharmacology of the two compounds.

Adult↗

A double blind comparison of zimelidine and amitriptyline in endogenous depression.

In a randomized double-blind group comparison study of 40 patients with endogenous depression zimelidine appeared to be as effective an antidepressant as amitriptyline at 4 and 6 weeks using the Hamilton Rating Scale (HRS) and the Montgomery and Asberg Depression Rating Scale (MADRS). At 2 weeks there was a significantly better response (P less than 0.05) on zimelidine compared to amitriptyline on the clinician's global scale and 4 out of 10 items on the MADRS suggesting an early onset of action. A significant better response to zimelidine was seen on the item somatic anxiety (HRS) while the effect on sleep and appetite was better in the amitriptyline group. There were significantly more side effects, raw and corrected, in the amitriptyline-treated group. High steady state plasma concentrations of norzimelidine (greater than 800 nmol/l) which were significantly correlated with age (r = 0.8) were associated with a significantly poorer response suggesting that a lower dose than 200 mg in older patients may be appropriate.

Adult↗

Mianserin plasma levels and differential clinical response in endogenous and reactive depression.

Fifty patients with moderate to severe primary depression were treated in equal groups of inpatients and outpatients with a constant dose of 60 mg. of mianserin daily for four weeks in a double blind placebo controlled trial with either a three times daily dosage regime or a single nightly dose. There was no difference in apparent compliance, side effects or therapeutic effect in either day-time or night-time dosage regimes. Patients developing high plasma levels of mianserin (greater than 70 microgram/l) were associated with a highly significantly poorer therapeutic outcome. Patients identified as endogenous depression demonstrated a significant negative correlation between plasma levels of mianserin and therapeutic response measured as an amelioration of either the Hamilton Rating Scale scores (r = --0.48) or on a new depression scale by Montgomery and Asberg (r = --0.51) with high levels associated with poor response. There was a significant correlation (r = 0.66) between mianserin plasma levels and age in endogenous depression. In those patients identified as suffering from reactive depression, no significant relationship could be seen between plasma levels and therapeutic response or with age. These findings support the view that the relationship between mianserin plasma levels and clinical response is more likely to be demonstrated in endogenous depression.

Adjustment Disorders↗